Tumor infiltrating lymphocyte therapy for human papillomavirus-positive cancers

肿瘤浸润淋巴细胞治疗人乳头瘤病毒阳性癌症

• 批准号: 8938145
• 负责人: Christian Hinrichs
• 金额: $ 28.26万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8938145
• 关键词: Adoptive Transfer; Anus; Clinical; Clinical Trials; Disease; Family psychotherapy; Human Papillomavirus; In Vitro; Laboratories; Laboratory Study; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Mediating; Metastatic Melanoma; Mutate; Oncogene Proteins; Oropharyngeal; Phenotype; Proteins; Specificity; T cell therapy; T-Lymphocyte; Testing; Time; Tumor-Infiltrating Lymphocytes; Vagina; Viral; Vulva; Work; base; in vivo; innovation; melanoma; response; tumor infiltrating lymphocyte therapy

The purpose of this project is to determine the objective clinical response rate of TIL therapy in HPV-positive cancers and to investigate the specificity, phenotype, and function of TIL from HPV-positive cancers in vitro and in vivo. Our laboratory has established the feasibility of generating TIL from HPV-positive cancers at clinical grade and scale. Based on that work we have initiated a clinical trial of TIL from HPV-positive cancers (HPV-TIL) with the primary end point of objective clinical response rate. The trial is open to accrual at this time. Laboratory studies to characterize HPV-TIL and to innovate the next generate of cellular therapies for this family of diseases are ongoing.

该项目的目的是确定 TIL 疗法在 HPV 阳性癌症中的客观临床反应率，并在体外和体内研究 HPV 阳性癌症中 TIL 的特异性、表型和功能。我们的实验室已经确定了在临床级别和规模上从 HPV 阳性癌症生成 TIL 的可行性。基于这项工作，我们启动了一项针对 HPV 阳性癌症 (HPV-TIL) 的 TIL 临床试验，主要终点是客观临床缓解率。目前该试验已开始计提。旨在表征 HPV-TIL 并创新针对该家族疾病的下一代细胞疗法的实验室研究正在进行中。